4.5 Review

Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations

Journal

EUROPEAN UROLOGY FOCUS
Volume 4, Issue 4, Pages 509-511

Publisher

ELSEVIER
DOI: 10.1016/j.euf.2018.08.005

Keywords

Bladder cancer; Urothelial cancer; Photodynamic therapy; Photoimmunotherapy; PDT; PIT; Hematoporphyrin; 5-Aminolevulinic acid; Hexaminolevulinic acid; BCG-refractory NMIBC

Funding

  1. Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research

Ask authors/readers for more resources

There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed photoimmunotherapy, which we will discuss in the last part of this report. (C) 2018 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available